Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo

Paul G. Tardi, Nancy Dos Santos, Troy O. Harasym, Sharon A. Johnstone, Natalia Zisman, Alan W. Tsang, David G. Bermudes and Lawrence D. Mayer
Paul G. Tardi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Dos Santos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Troy O. Harasym
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon A. Johnstone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia Zisman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan W. Tsang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David G. Bermudes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence D. Mayer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-09-0243 Published August 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: August 2009 to January 2021

AbstractFull-text HTMLPDF
Total384231872843

Cited By

Article Information

Volume 8, Issue 8, pp. 2266-2275

DOI 
https://doi.org/10.1158/1535-7163.MCT-09-0243
PubMed 
19671743

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received March 16, 2009
  • Revision received May 21, 2009
  • Accepted June 2, 2009
  • Published first August 11, 2009.

Article Versions

  • Previous version (August 11, 2009 - 08:30).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2009 American Association for Cancer Research.

Author Information

  1. Paul G. Tardi,
  2. Nancy Dos Santos,
  3. Troy O. Harasym,
  4. Sharon A. Johnstone,
  5. Natalia Zisman,
  6. Alan W. Tsang,
  7. David G. Bermudes and
  8. Lawrence D. Mayer
  1. Celator Pharmaceuticals Corp., Vancouver, British Columbia, Canada
  1. Requests for reprints:
    Paul G. Tardi, Celator Pharmaceuticals Corp., 1779 West 75th Avenue, Vancouver, British Columbia, Canada V6P 6P2. Phone: 604-675-2105; Fax: 604-708-5883. E-mail: ptardi{at}celatorpharma.com
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (8)
August 2009
Volume 8, Issue 8
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo
Paul G. Tardi, Nancy Dos Santos, Troy O. Harasym, Sharon A. Johnstone, Natalia Zisman, Alan W. Tsang, David G. Bermudes and Lawrence D. Mayer
Mol Cancer Ther August 1 2009 (8) (8) 2266-2275; DOI: 10.1158/1535-7163.MCT-09-0243

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo
Paul G. Tardi, Nancy Dos Santos, Troy O. Harasym, Sharon A. Johnstone, Natalia Zisman, Alan W. Tsang, David G. Bermudes and Lawrence D. Mayer
Mol Cancer Ther August 1 2009 (8) (8) 2266-2275; DOI: 10.1158/1535-7163.MCT-09-0243
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • A Novel TRAIL-Based Technology for Tumor Therapy
  • Trastuzumab Targeting of Metastatic Esophageal Cancer
  • Mcl-1 Determines the Fate of KSP-Inhibited Cells
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement